Monkasta (Montelukast)

Montelukast, the active ingredient in Monkasta, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It helps manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both adults and children as prescribed by a healthcare professional.

GNH USA supplies Monkasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides batch‑tested products with full documentation for regulatory compliance and reliable logistics support through global networks.

Montelukast acts on the leukotriene pathway to control inflammation and bronchoconstriction in respiratory disorders.

Asthma: reduces frequency of wheezing episodes and improves lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Mood changes including depression or suicidal thoughts - Hepatic injury or elevated liver enzymes

Before prescribing Monkasta, clinicians should consider several safety aspects.

Assess liver function: obtain baseline hepatic enzymes. Monitor neuropsychiatric symptoms: watch for depression or suicidal ideation. Avoid in patients with known hypersensitivity to montelukast. Use caution during pregnancy: weigh maternal benefit against potential risk. Adjust dose in severe hepatic impairment: follow specialist guidance. Store at room temperature: keep in the original container, protect from moisture.

Montelukast can interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase montelukast exposure. - CYP2C8 inducers (e.g., rifampicin, phenobarbital) may reduce therapeutic effect. - Concurrent use with another leukotriene receptor antagonist is not recommended.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect; monitor INR. - Beta‑agonists: additive bronchodilatory effect may occur. - Aspirin or NSAIDs: may increase risk of bronchospasm in aspirin‑sensitive individuals. - Antidepressants: may mask neuropsychiatric side effects.